Try our beta test site

Evaluation of Safety, Tolerability, Immunogenicity and Efficacy of a Novel Method in Specific Immunotherapy in Cat Allergic Patients: a Placebo Controlled Trial (IVN-CAT-001B)

This study has been completed.
Sponsor:
Collaborator:
ImVision GmbH, Hannover
Information provided by:
University of Zurich
ClinicalTrials.gov Identifier:
NCT00718679
First received: July 18, 2008
Last updated: February 10, 2010
Last verified: February 2010